Quotient (QTNT) Provides Update on MosaiQ Expanded Immunohematology Microarray CE Marking Progress
Get Alerts QTNT Hot Sheet
Join SI Premium – FREE
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced the company received feedback from the European notified body on the Expanded Immunohematology (IH) submission. The Company is pleased with the feedback and expects to submit a response to the questions in the next couple of weeks.
“I’m very pleased with the recent news and thankful for progress the team has made with this submission. I’m looking forward to executing on our commercialization in the first quarter of next year,” said Manuel O. Méndez, Chief Executive Officer of Quotient.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) Provides Update on the First Phase 3 YELLOWSTONE Trial of Oral Zeposia
- PayPal (PYPL) Appoint Carmine Di Sibio to its Board
- City Office REIT (CIO) Files $500M Mixed Shelf
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!